Cancer & SURVIVEiT News

The SURVIVEiT® NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

Progress!_

First-line brigatinib improves PFS for ALK-positive non-small cell lung cancer

First-line brigatinib improves PFS for ALK-positive non-small cell lung cancer September 27, 2018 First-line therapy with brigatinib significantly improved PFS compared with crizotinib among treatment-naive patients with advanced ALK-positive non-small cell lung...
Progress!_

World Lung 2018 – Alunbrig squares up to Xalkori, but the field is getting crowded

World Lung 2018 – Alunbrig squares up to Xalkori, but the field is getting crowded by Jacob Plieth Takeda's drug leads the charge of small-molecule tyrosine kinase inhibitors, some of...
mammogram-breast-cancer

Study shows value of breast cancer patients seeking second opinions

Study shows value of breast cancer patients seeking second opinions As scary as a cancer diagnosis can be, pausing to get more information can yield benefits Dawn Brazell | brazell@musc.edu | September 19,...
83_ellefson

Cancer Doesn’t Frighten Me

Cancer Doesn’t Frighten Me Living with advanced-stage lung cancer awakened me to live my best life. By Matt Ellefson, as told to Jo Cavallo September 25, 2018 In the fall...
Progress!_

Takeda Receives Positive CHMP Opinion Recommending (brigatinib) for Treatment of ALK+ NSCLC …

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib  Category: Small Molecules Published on Friday, 21 September...
New_FDA_Approval!

FDA approves moxetumomab pasudotox-tdfk for hairy cell leukemia

FDA approves moxetumomab pasudotox-tdfk for hairy cell leukemia On Sept. 13, 2018, the Food and Drug Administration approved moxetumomab pasudotox-tdfk (LUMOXITI, AstraZeneca Pharmaceuticals LP), a CD22-directed cytotoxin indicated for adult...
New_FDA_Approval!

Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma

Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma Naveed Saleh, MD, MS Sep 10, 2018 The United States Food and Drug Administration has announced the approval of mogamulizumab (Poteligeo) for...
cancer-patient-resting

DON’T BLAME RURAL CANCER PATIENTS FOR THEIR POORER HEALTH OUTCOMES

DON'T BLAME RURAL CANCER PATIENTS FOR THEIR POORER HEALTH OUTCOMES BY CHRISTOPHER CHENEY  |   AUGUST 23, 2018 The disparity between rural and urban cancer patients is best explained by differences in access...
New_FDA_Approval!

Imbruvica + rituximab becomes first non-chemo combination for Waldenström’s macroglobulinemia

Imbruvica + rituximab becomes first non-chemo combination for Waldenström’s macroglobulinemia The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of Imbruvica (ibrutinib) in combination with rituximab for...
dna-strands-4x6-v2

Tailored Drug Cocktails Offer Hope to Kids with Aggressive Brain Tumors

Tailored Drug Cocktails Offer Hope to Kids with Aggressive Brain Tumors Clinical Trial Tests Personalized Treatments in Push to Improve Pediatric Cancer Survival By Suzanne Leigh on August 29, 2018 UCSF Benioff Children’s...
Fearless Friday: Radiation Part II: How radiation oncologists think about treatment options

Fearless Friday: Radiation Part II: How radiation oncologists think about treatment options

Dr. Chad Rusthoven is back to discuss how treatments are selected for different types and stages of cancer. Please email us if there is anything we can do to help...
New_FDA_Approval!

FDA grants accelerated approval for 3rd line treatment of metastatic small cell lung cancer

FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer On August 16, 2018, the Food and Drug Administration granted accelerated approval to nivolumab (Opdivo, Bristol-Myers...